EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Setmelanotide Response Variability in Two Genetically Confirmed Pediatric Kidney Transplant Recipients with Bardet–Biedl Syndrome

Antonia Kondou iD, Pavlos Siolos iD, Georgia Sotiriou iD, Charalampos Agakidis, John Dotis iD, Athanasios Christoforidis iD, Nikoleta Printza iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27177740 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Antonia Kondou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Nephrology Unit, First Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hipp…. Hauptthemen laut MEDLINE: Kidney Transplantation, Bardet-Biedl Syndrome, alpha-MSH. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bardet–Biedl syndrome (BBS) is a genetically heterogeneous ciliopathy associated with hyperphagic obesity and kidney disease. Evidence on setmelanotide after pediatric kidney transplantation is limited. We evaluated two children with BBS treated with setmelanotide after kidney transplantation, collecting anthropometric, hunger, metabolic, graft-function, cyclosporine and genetic data. Patient 1, a 17-year-old boy with a homozygous pathogenic SDCCAG8 exon deletion, improved over 12 months: weight 55.6 to 48.0 kg, BMI 26.6 to 23.0 kg/m2, BMI-for-age z-score +1.60 to +0.43, maximal-hunger score 8/10 to 5/10, and HbA1c 6.5% to 5.1%. Patient 2, an 8-year-old girl with a homozygous likely pathogenic BBS5 splice-site variant and a heterozygous PCSK1 N221D variant, showed reduced hunger and an initial z-score fall from +6.10 to +5.69 by month 2.5, meeting the 0.2-point threshold for clinically meaningful change; this was not sustained, and BMI rose from 38.0 to 42.7 kg/m2 by eight months despite a dose of 3 mg/day. Graft function and cyclosporine trough concentrations remained stable, and skin hyperpigmentation was the only treatment-related adverse effect. In these two patients, setmelanotide was not associated with graft deterioration or altered cyclosporine trough concentrations, although two cases cannot establish safety. The divergent trajectories highlight interindividual variability; the role of PCSK1 N221D remains uncertain, and these observations are hypothesis-generating.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationBardet-Biedl Syndromealpha-MSHHumansChildAdolescentFemaleMaleProprotein Convertase 1Transplant Recipients

Stichwörter der Autor:innen

BBS5Bardet–Biedl syndromePCSK1SDCCAG8ciliopathyhyperphagiakidney transplantationmelanocortin-4 receptorpediatric obesitysetmelanotide

Substanzen

alpha-MSHsetmelanotideProprotein Convertase 1PCSK1 protein, human

Autor:innen und Institutionen

  • Pediatric Nephrology Unit, First Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece.
  • First Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece.
  • Pediatric Endocrinology and Diabetes Mellitus Unit, First Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, 54…
  • Third Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece.

ORCID-Profile: Antonia Kondou, Pavlos Siolos, Georgia Sotiriou, John Dotis, Athanasios Christoforidis, Nikoleta Printza

Zitieren

APA

Kondou, A., Siolos, P., Sotiriou, G., Agakidis, C., Dotis, J., Christoforidis, A., & Printza, N. (2026). Setmelanotide Response Variability in Two Genetically Confirmed Pediatric Kidney Transplant Recipients with Bardet–Biedl Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177740

Vancouver

Kondou A, Siolos P, Sotiriou G, Agakidis C, Dotis J, Christoforidis A, et al. Setmelanotide Response Variability in Two Genetically Confirmed Pediatric Kidney Transplant Recipients with Bardet–Biedl Syndrome. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177740

BibTeX
@article{Kondou2026,
  author = {Kondou, Antonia and Siolos, Pavlos and Sotiriou, Georgia and Agakidis, Charalampos and Dotis, John and Christoforidis, Athanasios and Printza, Nikoleta},
  title = {Setmelanotide Response Variability in Two Genetically Confirmed Pediatric Kidney Transplant Recipients with Bardet–Biedl Syndrome},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27177740}
}
Kostenlos starten →